Loading...
•
Mar 31, 2021
Personalis Q1 2021 Earnings Report
Reported record revenue and nineteenth consecutive quarter of growth.
Key Takeaways
Personalis, Inc. reported record quarterly revenue of $20.9 million in the first quarter of 2021, a 9% increase compared to the first quarter of 2020. The company's revenue from biopharma and all other customers, excluding VA MVP, grew 74% year-over-year.
Record quarterly revenue of $20.9 million, a 9% increase year-over-year.
Revenue from biopharma and all other customers, excluding VA MVP, increased by 74% year-over-year.
Announced collaborations with Natera and MapKure.
Added approximately $162 million of cash from a public offering, ending the quarter with $353.4 million in cash, cash equivalents, and short-term investments.
Forward Guidance
Personalis expects total company revenues of approximately $21.3 million and a net loss in the range of $16 million to $17 million for the second quarter of 2021. For the full year 2021, the company anticipates total company revenues of approximately $85 million and a net loss in the range of $70 million to $75 million.
Positive Outlook
- Total Company revenues to be approximately $21.3 million for Q2 2021.
- Revenues from biopharma and all other customers, excluding VA MVP, to be in the range of $7.3 million to $7.7 million for Q2 2021.
- Total Company revenues to be approximately $85 million for the full year of 2021.
- Revenues from biopharma and all other customers, excluding VA MVP, to be in the range of $30 million to $32 million for the full year of 2021.
Challenges Ahead
- Net Loss to be in the range of $16 million to $17 million for Q2 2021.
- Estimated outstanding shares of 43 million for Q2 2021.
- Net Loss to be in the range of $70 million to $75 million for the full year of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...